247 related articles for article (PubMed ID: 34202213)
1. Clinicopathological and Genomic Profiles of Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma Identify Overlapping Signatures with a High Mutational Burden.
Ak M; Kahraman A; Arnold FM; Turko P; Levesque MP; Zoche M; Ramelyte E; Dummer R
Genes (Basel); 2021 Jun; 12(7):. PubMed ID: 34202213
[TBL] [Abstract][Full Text] [Related]
2. Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1/2 and FAT1 mutations and similar DNA copy number alteration profiles.
Griewank KG; Wiesner T; Murali R; Pischler C; Müller H; Koelsche C; Möller I; Franklin C; Cosgarea I; Sucker A; Schadendorf D; Schaller J; Horn S; Brenn T; Mentzel T
Mod Pathol; 2018 Mar; 31(3):418-428. PubMed ID: 29099504
[TBL] [Abstract][Full Text] [Related]
3. Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas.
Helbig D; Ihle MA; Pütz K; Tantcheva-Poor I; Mauch C; Büttner R; Quaas A
Oncotarget; 2016 Apr; 7(16):21763-74. PubMed ID: 26943575
[TBL] [Abstract][Full Text] [Related]
4. Pleomorphic dermal sarcoma in a man with HIV: report with next-generation sequencing analysis and review of the atypical fibroxanthoma/pleomorphic dermal sarcoma spectrum.
Chen SX; Eichenfield DZ; Orme C; Hinds B
Dermatol Online J; 2019 Nov; 25(11):. PubMed ID: 32045146
[TBL] [Abstract][Full Text] [Related]
5. A genomic survey of sarcomas on sun-exposed skin reveals distinctive candidate drivers and potentially targetable mutations.
Miller TI; Zoumberos NA; Johnson B; Rhodes DR; Tomlins SA; Chan MP; Andea AA; Lucas DR; McHugh JB; Smith N; Harms KL; Brewer C; Saleh J; Patel RM; Harms PW
Hum Pathol; 2020 Aug; 102():60-69. PubMed ID: 32540221
[TBL] [Abstract][Full Text] [Related]
6. TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas.
Griewank KG; Schilling B; Murali R; Bielefeld N; Schwamborn M; Sucker A; Zimmer L; Hillen U; Schaller J; Brenn T; Schadendorf D; Mentzel T
Mod Pathol; 2014 Apr; 27(4):502-8. PubMed ID: 24030750
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical expression of melanocytic and myofibroblastic markers and their molecular correlation in atypical fibroxanthomas and pleomorphic dermal sarcomas.
Helbig D; Mauch C; Buettner R; Quaas A
J Cutan Pathol; 2018 Dec; 45(12):880-885. PubMed ID: 30155964
[TBL] [Abstract][Full Text] [Related]
8. Pleomorphic Dermal Sarcoma.
Saleh JS; Whittington CP; Bresler SC; Patel RM
Surg Pathol Clin; 2024 Mar; 17(1):153-158. PubMed ID: 38278604
[TBL] [Abstract][Full Text] [Related]
9. Conception and Management of a Poorly Understood Spectrum of Dermatologic Neoplasms: Atypical Fibroxanthoma, Pleomorphic Dermal Sarcoma, and Undifferentiated Pleomorphic Sarcoma.
Soleymani T; Tyler Hollmig S
Curr Treat Options Oncol; 2017 Aug; 18(8):50. PubMed ID: 28762020
[TBL] [Abstract][Full Text] [Related]
10. Increase of atypical fibroxanthoma and pleomorphic dermal sarcoma: a retrospective analysis of four German skin cancer centers.
Kuntz T; Siebdrath J; Hofmann SC; Baltaci M; Schaller J; Hellmich M; von Goltzheim LS; Assaf C; Oellig F; Michalowitz AL; Helbig D; Kreuter A
J Dtsch Dermatol Ges; 2022 Dec; 20(12):1581-1588. PubMed ID: 36442137
[TBL] [Abstract][Full Text] [Related]
11. Clear cell variant of atypical fibroxanthoma and pleomorphic dermal sarcoma: Molecular characterization and review of the literature.
Coelho-Lima J; Bruty J; Watkins J; Liu H; Price R; Stefanos N
J Cutan Pathol; 2022 Dec; 49(12):1031-1034. PubMed ID: 35922373
[TBL] [Abstract][Full Text] [Related]
12. S1-guideline atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS).
Helbig D; Ziemer M; Dippel E; Erdmann M; Hillen U; Leiter U; Mentzel T; Osterhoff G; Ugurel S; Utikal J; von Bubnoff D; Weishaupt C; Grabbe S
J Dtsch Dermatol Ges; 2022 Feb; 20(2):235-243. PubMed ID: 35099104
[TBL] [Abstract][Full Text] [Related]
13. Atypical fibroxanthoma and pleomorphic dermal sarcoma: Is superficial infiltration in subcutaneous tissue acceptable in AFX?
van Midden D; Flucke UE; Amir AL; Bonenkamp JJ; Lubeek SFK; Blokx WAM
Ann Diagn Pathol; 2022 Jun; 58():151915. PubMed ID: 35276548
[TBL] [Abstract][Full Text] [Related]
14. Somatic Mutation Profile of Atypical Fibroxanthoma and Cutaneous Undifferentiated Pleomorphic Sarcoma.
Lim YH; Zaki TD; Levinsohn JL; Galan A; Choate KA; Hanlon AM
Dermatol Surg; 2021 Feb; 47(2):290-292. PubMed ID: 32079866
[No Abstract] [Full Text] [Related]
15. Pleomorphic Dermal Sarcoma: A Clinical and Histopathologic Emulator of Atypical Fibroxanthoma, but Different Biologic Behavior.
Carletti M; Nguyen DA; Malouf P; Ingersoll Z; Hosler GA; Weis SE
HCA Healthc J Med; 2022; 3(5):299-304. PubMed ID: 37425251
[TBL] [Abstract][Full Text] [Related]
16. Atypical fibroxanthoma and pleomorphic dermal sarcoma: A reappraisal.
Cesinaro AM; Gallo G; Tramontozzi S; Migaldi M
J Cutan Pathol; 2021 Feb; 48(2):207-210. PubMed ID: 32583897
[TBL] [Abstract][Full Text] [Related]
17. LN2, CD10, and Ezrin Do Not Distinguish Between Atypical Fibroxanthoma and Undifferentiated Pleomorphic Sarcoma or Predict Clinical Outcome.
Hanlon A; Stasko T; Christiansen D; Cyrus N; Galan A
Dermatol Surg; 2017 Mar; 43(3):431-436. PubMed ID: 28079637
[TBL] [Abstract][Full Text] [Related]
18. Atypical fibroxanthoma: new insights.
Hussein MR
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1075-88. PubMed ID: 24958232
[TBL] [Abstract][Full Text] [Related]
19. Pleomorphic dermal sarcoma: adverse histologic features predict aggressive behavior and allow distinction from atypical fibroxanthoma.
Miller K; Goodlad JR; Brenn T
Am J Surg Pathol; 2012 Sep; 36(9):1317-26. PubMed ID: 22510760
[TBL] [Abstract][Full Text] [Related]
20. Oncological Safety and Recurrence in the Surgical Treatment of Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma of the Scalp.
Zeller J; Kiefer J; Braig D; Winninger O; Kraus D; Hagelstein S; Eisenhardt SU
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
